Clinical Trials Sponsored by Shanghai Zerun Biotechnology Co.,Ltd

Total 1405 results

Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)

HER2-positive Breast Cancer

China
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 (WX-081)

Pulmonary Tuberculosis

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Active, not recruiting

Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects

Alzheimer's Disease

China
Shanghai Bao Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

Healthy

New Zealand
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

An Evaluation of 9MW1911 Injection in Healthy Subjects

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT)

Triple-Negative Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

Preoperative Sedation of Children

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Drug-drug Interaction Study of SPH3127

Drug Drug Interaction

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Nuance Pharma (shanghai) Co., Ltd

Completed

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Healthy Subjects

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Trial of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
Shanghai Pharmaceuticals Holding Co., Ltd

Not yet recruiting

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

China
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

Aromatic L-amino Acid Decarboxylase Deficiency
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma
Shanghai Shengdi Pharmaceutical Co., Ltd

Recruiting

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Glutaric Acidemia Type I | Glutaric Aciduria Type I

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Atopic Dermatitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

Migraine

China
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor

China
Monyan Pharmaceutical (Shanghai) Co., Ltd.

Recruiting

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Heart Failure | Cancer | Arrhythmia | Doxorubicin Induced Cardiomyopathy | Doxorubicin Adverse Reaction

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of HY-0102 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Lupus Erythematosus, Systemic

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

Advanced Solid Tumor

China

Clinical Trials Sponsored by Shanghai Zerun Biotechnology Co.,Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations